Publish in this journal
Journal Information
Vol. 91. Issue 2.
Pages 122-124 (01 August 2019)
Vol. 91. Issue 2.
Pages 122-124 (01 August 2019)
Scientific Letter
DOI: 10.1016/j.anpede.2018.09.008
Open Access
How do we treat Kaposiform haemangioendothelioma?
¿Cómo tratamos el hemangioendotelioma kaposiforme?
Visits
60
Sergi Huerta-Calpea,
Corresponding author
huerta_sercal@gva.es

Corresponding author.
, Alejandro Pinilla-Gonzáleza, Antonio Juan Ribellesb, Javier Gómez-Chacón Villalbac, Santiago Pérez-Tarazonad
a Servicio de Pediatría, Hospital la Fe, Valencia, Spain
b Sección de Hemato-Oncología Infantil, Hospital la Fe, Valencia, Spain
c Servicio de Cirugía Pediátrica, Hospital la Fe, Valencia, Spain
d Servicio de Neonatología, Hospital la Fe, Valencia, Spain
This item has received
60
Visits

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Full Text
Dear Editor:

Kaposiform haemangioendothelioma (KHE) is a rare, vascular tumour that has little metastatic potential but can be locally aggressive and may be life-threatening. It is diagnosed based on the findings of imaging tests and gross and histological features. It usually presents as a single lesion in the retroperitoneum or subcutaneous tissue, and in 30% of cases it is associated with Kasabach–Merritt syndrome (KMS), a coagulopathy that has complications that are more severe than those of KHE alone. The Sociedad Española de Hematología y Oncología Pediátrica (Spanish Society of Paediatric Haematology and Oncology) proposes surgical resection as first-line treatment, but the involvement of vital structures may preclude this option. In such cases, the use of a combination of antiplatelet therapy and systemic corticosteroid therapy is recommended for first-line treatment, reserving treatment with vincristine, cyclophosphamide, interferon alfa or other cytostatic agents for refractory cases.1

We present the 3 cases of KHE managed in the past decade in our tertiary care hospital, one of whom was a patient with underlying sickle cell disease, a comorbidity that has not been described previously.

Case 1: full-term infant with a congenital violaceous cervical mass, hard to de touch and extending from the left retroauricular area to the edge of the right preauricular area (Fig. 1). A magnetic resonance image (MRI) scan confirmed the diagnosis of KHE (Fig. 2). The patient presented with thrombocytopenia (25000/dL) and d-dimer elevation (3000μg/L), which suggested the additional presence of KMS. Treatment started with methylprednisolone, antiplatelet therapy and vincristine, which resulted in transient improvement. This was followed by a drop in the platelet count to 5000/dL in the context of necrotizing enterocolitis. Cyclophosphamide was added to the treatment, followed by sirolimus due to nonresponse, which achieved a gradual decrease in tumour size and normalization of the laboratory test results. The patient underwent surgical resection of the mass at age 13 months. At age 22 months, the patient continues to be healthy and without recurrence.

Figure 1.

Congenital violaceous cervical mass.

(0.06MB).
Figure 2.

MRI. Heterogeneous hyperintense lesion on T2-weighted image.

(0.05MB).

Case 2: girl aged 2 years brought for consultation after detection of an abdominal mass in the course of a febrile illness. The findings of the ultrasound examination, MRI scan and biopsy confirmed the diagnosis of KHE restricted to the muscles of the right abdominal wall, with no laboratory abnormalities suggestive of KMS at onset. Treatment started with methylprednisolone, but it was switched to vincristine after 3 weeks due to nonresponse. After the fifth dose, there was evidence of thrombocytopenia (3000/dL) and d-dimer elevation (12400μg/L) compatible with KMS. This was followed by intraarterial embolization of the tumour by interventional radiology, with little improvement. Since the patient showed little progress, vincristine was discontinued and replaced by everolimus, which achieved a reduction of the tumour. The patient underwent resection of the tumour at age 4 years. At present, the patient is 6 years old and remains disease-free.

Case 3: infant aged 7 months with sickle cell disease presenting with a hard lump in the deep planes of the left arm. After 3 months of follow-up during which a vaso-occlusive crisis had been suspected, the mass increased in size, leading to performance of a biopsy and a confirmed diagnosis of KHE. Although the initial laboratory test results had been normal, at this point the patient exhibited sudden thrombocytopenia (26000/dL) and d-dimer elevation (4430μg/L), suggestive of KMS. Treatment was initiated with vincristine, which achieved a reduction of the tumour size and normalization of the laboratory test results. After the seventh dose, the patient experienced sudden deterioration and was brought to the emergency department with cardiac arrest. The patient exhibited marked splenomegaly, which suggested splenic sequestration secondary to the underlying sickle cell disease. After advanced cardiopulmonary resuscitation failed, the patient was declared dead.

The cases presented here illustrate the considerable heterogeneity found in the management of this disease. Furthermore, given the low incidence of KHE, the literature on the subject is limited to a few case series. This evinces a need for updated guidelines including new therapeutic alternatives. The use of corticosteroids has not been assessed in clinical trials, and most published studies have reported a partial response or a lack of effectiveness when used as monotherapy. Selective tumour embolization seems to achieve a transient improvement in tumour size and platelet counts, so it may be indicated in severe cases as an adjuvant to medical treatment. Total surgical resection, when feasible, is usually the most effective treatment. In some cases, vincristine has achieved complete resolution of the tumour and normalization of laboratory tests.2 Propranolol also appears to be useful in the management of KHE, although the results on this subject are contradictory.3,4 Clinical trials and case studies are currently underway to investigate the use of sirolimus and other mTOR inhibitors, so far with promising results,5,6 and some hospitals are using these drugs as first-line treatment. Although it is a challenging task on account of the low incidence of KHE, there is a clear need for comparative studies of currently used and newly proposed treatments for the purpose of updating management guidelines.

References
[1]
R. López Almaraz, J.C. López Gutiérrez, C. Belendez Bieler, Herrero Hernández, M.E. Mateos González, G. Ramírez Villar.
Tumores vasculares en la infancia.
An Pediatr (Barc), 72 (2010), pp. 143
[2]
R. Garcia-Monaco, A. Giachetti, O. Peralta, N. Napoli, P. Lobos, L. Gioseffi, et al.
Kaposiform hemangioendothelioma with Kasabach–Merritt phenomenon: successful treatment with embolization and vincristine in two newborns.
J Vasc Interv Radiol, 23 (2012), pp. 417-422
[3]
L. Filippi, A. Tamburini, E. Berti, A. Perrone, C. Defilippi, C. Favre, et al.
Successful propranolol treatment of a kaposiform hemangioendothelioma apparently resistant to propranolol.
Pediatr Blood Cancer, 63 (2016), pp. 1290-1292
[4]
Y. Chiu, B. Drolet, F. Blei, M. Carcao, J. Fangusaro, M. Kelly, et al.
Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach–Merritt phenomenon.
Pediatr Blood Cancer, 59 (2012), pp. 934-938
[5]
H. Lackner, A. Karastaneva, W. Schwinger, M. Benesch, P. Sovinz, M. Seidel, et al.
Sirolimus for the treatment of children with various complicated vascular anomalies.
Eur J Pediatr, 174 (2015), pp. 1579-1584
[6]
T. Uno, S. Ito, A. Nakazawa, O. Miyazaki, T. Mori, K. Terashima.
Successful treatment of kaposiform hemangioendothelioma with everolimus.
Pediatr Blood Cancer, 62 (2014), pp. 536-538

Please cite this article as: Huerta-Calpe S, Pinilla-González A, Juan Ribelles A, Gómez-Chacón Villalba J, Pérez-Tarazona S. ¿Cómo tratamos el hemangioendotelioma kaposiforme? An Pediatr (Barc). 2019;91:122–124.

Copyright © 2018. Asociación Española de Pediatría
Idiomas
Anales de Pediatría (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.